Skip to Content

VESIcare Approval History

FDA Approved: Yes (First approved November 19, 2004)
Brand name: VESIcare
Generic name: solifenacin
Dosage form: Tablets
Company: Yamanouchi / GlaxoSmithKline
Treatment for: Overactive Bladder

VESIcare (solifenacin) is a muscarinic receptor antagonist treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Development History and FDA Approval Process for VESIcare

DateArticle
Nov 19, 2004Approval Vesicare Yamanouchi / GlaxoSmithKline - Treatment for Overactive Bladder

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide